NCT04009317 2019-10-30Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3 Unknown260 enrolled